EUVIMEDEUVIMED entdecken
Multizentrische Studie

Idiopathic Multicentric Castleman Disease— TAFRO : A Potentially Curable Disease?

Lu Zhang iD, Jia-Ying Ge iD, Si-Yuan Li iD, Hong-Yan Tong iD, Liang-Shun You iD, Jian Li iD

American Journal of Hematology · 2026-03 · 101 (3) · 447-455

DOI: 10.1002/ajh.70199 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 10.01.2026. Verfasst von Lu Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Castleman Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences (CIFMS), Peking Union Medical College Hospital Talent Cultivation Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic multicentric Castleman disease (iMCD)‐TAFRO (Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis/renal dysfunction, Organomegaly) is the most severe clinical subtype of iMCD characterized by a catastrophic cytokine storm. Currently, iMCD‐TAFRO is regarded as incurable which needs “indefinite” treatment. However, long‐term data are sparse, and treatment discontinuation may be possible in a subset of patients. This multicenter, retrospective study analyzed 27 patients who discontinued treatment. All patients had biochemical complete response (CR) at the time of drug discontinuation. Most patients were treated with myeloma‐like treatment (59.3%) and only 11.1% received anti‐IL‐6 therapy. With a median follow‐up of 31 months (range, 12–108) after treatment discontinuation, only four patients (14.8%) suffered from progression of disease (PD) and the others (85.2%) maintained biochemical CR. Patients who suffered from PD had a significantly lower pretreatment CRP level than patients maintaining responses (43.7 ± 39.3 vs. 126.4 ± 62.5 mg/L, p = 0.018). No significant impacts of different treatment approaches or duration of treatment on the likelihood of achieving long‐term remission were observed. The median time between drug discontinuation to PD ( n = 4) was 9.5 months (range, 5–12). These patients all achieved treatment responses again with the same or similar treatment approaches. The estimated PFS at 6 months, 1 year, and 3 years were 96.3%, 85.2%, and 85.2%, respectively. All patients remained alive with a median of 31 months follow‐up after drug discontinuation. This study suggests that some iMCD‐TAFRO patients might maintain long‐term remission after treatment discontinuation. For patients who achieved biochemical CR, an attempt at treatment discontinuation could be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Castleman DiseaseHumansFemaleRetrospective StudiesMaleMiddle AgedAdultAgedDisease ProgressionRemission InductionFollow-Up StudiesTreatment Interruption

Stichwörter der Autor:innen

curable diseasedrug discontinuationiMCD‐TAFROidiopathic multicentric Castleman diseaselong‐term remission

Autor:innen und Institutionen

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Lu Zhang, Jia-Ying Ge, Si-Yuan Li, Hong-Yan Tong, Liang-Shun You, Jian Li

Förderung

  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • Peking Union Medical College Hospital Talent Cultivation Program
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, L., Ge, J. Y., Li, S. Y., Tong, H. Y., You, L. S., & Li, J. (2026). Idiopathic Multicentric Castleman Disease— TAFRO : A Potentially Curable Disease?. American Journal of Hematology, 101(3), 447-455. https://doi.org/10.1002/ajh.70199

Vancouver

Zhang L, Ge JY, Li SY, Tong HY, You LS, Li J. Idiopathic Multicentric Castleman Disease— TAFRO : A Potentially Curable Disease?. American Journal of Hematology. 2026;101(3):447-455. doi:10.1002/ajh.70199

BibTeX
@article{Zhang2026,
  author = {Zhang, Lu and Ge, Jia-Ying and Li, Si-Yuan and Tong, Hong-Yan and You, Liang-Shun and Li, Jian},
  title = {Idiopathic Multicentric Castleman Disease— TAFRO : A Potentially Curable Disease?},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {3},
  pages = {447--455},
  doi = {10.1002/ajh.70199}
}
Kostenlos starten →